High-Dose Busulfan and Myoclonic Epilepsy

Letters and Corrections1 January 1987High-Dose Busulfan and Myoclonic EpilepsyR. W. MARTELL, F.C.P.(S.A.), C. SHER, M.B., Ch.B., P. JACOBS, M.D., Ph.D., F. MONTEAGUDO, F.C.P.(S.A.)R. W. MARTELL, F.C.P.(S.A.)Search for more papers by this author, C. SHER, M.B., Ch.B.Search for more papers by this author, P. JACOBS, M.D., Ph.D.Search for more papers by this author, F. MONTEAGUDO, F.C.P.(S.A.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-106-1-173_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We report what we believe to be a unique toxic effect of high-dose busulfan occurring in a 42-year-old woman with acute myeloid leukemia in second remission.The patient had been receiving ethambutol, isoniazid, and rifampicin for tuberculous hepatitis for 3 months. One week before infusion of cryopreserved autologous marrow, she began treatment with busulfan, in four divided doses of 4 mg/kg · d for 4 days (total dose, 60 mg every 6 hours). Simultaneously, she was given metoclopramide, 20 mg every 8 hours; domperidone, 10 mg every 8 hours; and dexamethasone, 2 mg every 8 hours, for...References1. LUBRAINEKAIZERSARALTUTSCHKASANTOS CHHRPG. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep. 1984;68:711-7. MedlineGoogle Scholar2. HYSERDRAKE CM. Myoclonus induced by metoclopramide therapy. Arch Intern Med. 1983;143:2201-2. CrossrefMedlineGoogle Scholar3. WEAVINGBEZWODADERMAN AWD. Seizures after antiemetic treatment with high dose domperidone: report of four cases. Br Med J. 1984;288:1728. CrossrefMedlineGoogle Scholar4. SANTOSTUTSCHKABROOKMEYER GPR. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-53. CrossrefMedlineGoogle Scholar5. BLAZERRAMSAYKERSEYKRIVITARTHURFILIPOVICH BNJWD. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Transplantation. 1985;39:597-603. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Cape Town Leukaemia Centre Groote Schuur Hospital Observatory 7925, Cape Town South Africa PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAcute symptomatic seizures during haematopoietic stem cell transplantationHematopoietic Stem Cell Transplantation in Elderly Patients with Myelodisplastic Syndrome and Acute Myelogenous Leukemia: Use of Busulfan/Fludarabine for ConditioningBusulfan in Hematopoietic Stem Cell TransplantationThe role of busulfan in bone marrow transplantationAspects Concerning Busulfan Pharmacokinetics and BioavailabilityInfluence of prophylactic anticonvulsant therapy on high-dose busulphan kineticsPretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective studyIn vivo distribution of [11C]-busulfan incynomolgus monkey and in the brain of a human patientGeneralized Seizures Secondary to High-Dose Busulfan Therapy11C-labeling of busulphanThe effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicityBusulphan and PhenytoinAndrew P. Grigg, MD, John D. Shepherd, MD, Gordon L. Phillips, MDHigh-Dose Busulfan and SeizuresA. Sureda, MD, J. Pérez de Oteyza, MD, J. García Laraña, MD, J. Odriozola, MD, PhD 1 January 1987Volume 106, Issue 1Page: 173-173KeywordsAcute myeloid leukemiaBone marrowEpilepsyHepatitisIsoniazid Issue Published: 1 January 1987 PDF DownloadLoading ...